Zenas BioPharma, Inc.
ZBIO
$19.16
-$1.24-6.08%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -357.08% | -33.39% | -37.51% | -20.77% | -113.95% |
| Total Depreciation and Amortization | -69.70% | -69.44% | -65.71% | -30.30% | 10.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3,388.70% | 372.61% | 190.64% | 197.61% | 223.96% |
| Change in Net Operating Assets | -6.21% | -180.63% | 0.04% | -229.03% | 17.17% |
| Cash from Operations | -35.95% | -32.41% | -34.83% | -93.96% | -150.35% |
| Capital Expenditure | 100.00% | -- | 100.00% | 18.18% | -335.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2,450.23% | 249.64% | -- | -- | -- |
| Cash from Investing | -2,399.71% | 249.64% | -320,731.43% | -392,054.55% | -21,870.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,274.08% | -99.60% | 1,288.71% | 135.71% | 12,552.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -108.83% | 16,427.11% | -- | -- | -- |
| Cash from Financing | 7,500.81% | -68.96% | -99.03% | 116.12% | 3,606.00% |
| Foreign Exchange rate Adjustments | -92.20% | 148.08% | -837.50% | -244.44% | 262.07% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 87.78% | -59.37% | -203.93% | -525.71% | -160.74% |